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Background: Neuropathic diabetic foot ulceration may be prevented if the mechanical stress transmitted to the
plantar tissues is reduced. Insole therapy is one practical method commonly used to reduce plantar loads and
ulceration risk. The type of insole best suited to achieve this is unknown. This trial compared custom-made
functional insoles with prefabricated insoles to reduce risk factors for ulceration of neuropathic diabetic feet.
Method: A participant-blinded randomised controlled trial recruited 119 neuropathic participants with diabetes
who were randomly allocated to custom-made functional or prefabricated insoles. Data were collected at issue and
six month follow-up using the F-scan in-shoe pressure measurement system. Primary outcomes were: peak
pressure, forefoot pressure time integral, total contact area, forefoot rate of load, duration of load as a percentage
of stance. Secondary outcomes were patient perceived foot health (Bristol Foot Score), quality of life (Audit of
Diabetes Dependent Quality of Life). We also assessed cost of supply and fitting. Analysis was by intention-to-treat.
Results: There were no differences between insoles in peak pressure, or three of the other four kinetic measures.
The custom-made functional insole was slightly more effective than the prefabricated insole in reducing forefoot
pressure time integral at issue (27% vs. 22%), remained more effective at six month follow-up (30% vs. 24%,
p=0.001), but was more expensive (UK £656 vs. £554, p<0.001). Full compliance (minimum wear 7 hours a day 7
days per week) was reported by 40% of participants and 76% of participants reported a minimum wear of 5 hours
a day 5 days per week. There was no difference in patient perception between insoles.
Conclusion: The custom-made insoles are more expensive than prefabricated insoles evaluated in this trial and no
better in reducing peak pressure. We recommend that where clinically appropriate, the more cost effective
prefabricated insole should be considered for use by patients with diabetes and neuropathy.
Trial registration: Clinical trials.gov (NCT00999635). Note: this trial was registered on completion.Background
Peak plantar pressure is linked to the formation of
neuropathic foot ulcers [1,2]. Reducing plantar pressure
forms one important element of the ulcer prevention
strategy, particularly in neuropathic feet with reduced or
absent protective sensation, where plantar loads and tissue
stress are increased [3-6]. Yet there are no good quality
randomised controlled trials investigating the efficacy of* Correspondence: joanne.paton@plymouth.ac.uk
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reproduction in any medium, provided the oroffloading interventions for pressure reduction and
ulcer prevention amongst individuals with diabetes
and neuropathy [4,7].
Traditionally used, custom-made moulded insoles may
reduce peak pressure by maximising total plantar contact
area [8], but this method of pressure relief may not fully
compensate for the underlying biomechanical foot dysfunc-
tion accompanying diabetic neuropathy. Biomechanical
foot dysfunction influences plantar load distribution and
mechanical tissue stress [9,10]. Greater influence over plan-
tar loads and tissue stress may result if a more functionaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of altered foot biomechanics. Few studies have investigated
the application of biomechanical principles to reduce plan-
tar tissue stress under diabetic neuropathic feet.
The main hypothesis of this study was that custom-
made functional insoles would reduce risk factors intrinsic
to the foot, in particular peak pressure, for neuropathic
ulcers in diabetic feet over six months compared to pre-
fabricated moulded insoles. However, given the limitations
of peak pressure described above, we examined changes in
four other kinetic variables: total contact area, forefoot
pressure time integral, rate of forefoot load, and duration
of load as a percentage of stance. Two preliminary studies
were undertaken to select and test the suitability of the
five kinetic outcome measures for purpose [11,12]. We
also assessed patient-perceived foot health, health-related
quality of life and cost.
Methods
Ethics
Ethics approval was granted by the Cornwall and
Plymouth Research Ethics Committee (REC number:
05/Q2103/150).
Design and sample size
This participant-blinded randomised controlled trial
compared custom-made functional insoles with prefabri-
cated moulded insoles to reduce abnormal plantar loads
and tissue stress, risk factors for neuropathic ulcers in
diabetic feet, over six months. Sample size was based on
change in peak pressure using values sourced from
Barnett [13]; she found a difference between 346.4 kPa
for a moulded insole and 296.4 kPa for an inlay (stand-
ard deviation 80.1 kPa). A sample size of 54 in each
group provided 90% power at p = 0.05, for a two-tailed
test on peak pressure. The sample size was increased by
10% to allow for patient dropout giving a total of n=119.
Recruitment
From March 2006 to October 2007, 119 consecutive
patients fulfilling the enrolment criteria, attending for
podiatry treatment and providing informed consent,
were recruited at two centres in South West England.
Patients were eligible if they: had Type 1 or 2 diabetes;
had insensate or diminished sensation, defined as a def-
icit noted with the 10g monofilament and 128Hz tuning
fork, using the method previously described [14]; had
palpable or biphasic pulses; had not had a lower limb
vascular or neuropathic ulceration (for at least the past
six months); scored Grade 0 on the Wagner classifica-
tion for foot ulcer; were able to walk a minimum of
10 metres unaided; and were willing to comply with the
requirements of the study. Patients were excluded if
they presented with severe fixed midfoot or rearfootdeformity such as that associated with Charcot arthropa-
thy, a history of major bone or joint surgery of the lower
limb, or were unable to comprehend simple instructions
and comply with the study protocol.
Randomisation and blinding
Participants were randomised in equal proportions to
custom-made or prefabricated insoles, in blocks of six,
independently for the two recruiting centres. Random-
isation allocation was prepared by Plymouth University
Statistics Department prior to patient recruitment. The
primary investigator was blind to the intervention alloca-
tion until treatment commenced. Treatment allocation
was revealed to the primary investigator by an independent
observer following biomechanical examination, the casting
of the foot and prescribing of insole and footwear. The
clinical trial design was only single blind to accommodate
unavoidable ethical and practical concerns regarding
potential adverse effect. Participants remained blind to the
intervention group assignment. At discharge from the trial,
participants were asked to guess their intervention group
assignment, providing estimates of the degree to which the
blind allocation was maintained.
Insoles
Based on the results of pilot work previously described
[15], the insoles were constructed from a blue, medium
density, 3 mm full length moulded ethylene vinyl acetate
(EVA) base with a 6 mm full-length grey PoronW top
cover. Although the two insoles had similar appearance
they differed in design and construction.
Custom-made functional insole
Each custom-made functional device was unique, fabri-
cated from a cast of each individual foot, and prescribed
and custom-manufactured to address individual bio-
mechanical need in accordance with the prescription
writing protocol. No detailed published prescription
writing guidelines could be found for the treatment of
this patient group. Therefore, a prescription writing
protocol was devised for the trial based upon a critical
analysis of the literature (See Additional file 1: Summary
of prescription writing protocol and rational). A single
experienced clinician conducted the lower limb biomech-
anical examination, obtained the foam box foot impres-
sion and wrote the insole prescription. The custom-made
functional 3 mm EVA shells were milled from the cast
using CAD/CAM technology (Figure 1).
Prefabricated insole
The prefabricated insole was ‘off the shelf ’ and provided to
fit the shoe. First Line Full Length Orthotics (Talarmade
Ltd) consisted of a prefabricated full-length 3 mm medium
EVA contoured shell covered in 6 mm PoronW (Figure 1).
Custom-made functional insole
Prefabricated insole
Figure 1 Example of the insoles used within the trial.
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examination, casting and insole prescription writing
process was undertaken using the same technique as for
the custom-made functional group, but were not used.
Therapeutic footwear
Participants were also fitted with two pairs of modular
non-bespoke therapeutic footwear self-selected from a
choice of style and colour. The footwear incorporated
the following specifications for patients with diabetes;
softee leather upper, plain vamp, secure fastening, micro
fibre lining material, padded collar, wall toe puff and a
EVA micro rubber sole unit with rocker to forefoot posi-
tioned posterior to metatarsophlangeal joint line
(County Orthopaedic Footwear Ltd).
Primary outcome measures
Changes in kinetics were compared using the F-scanW
in-shoe pressure analysis system (TEKSCANW Ltd) be-
tween participants with custom-made functional and
prefabricated insoles. Data were collected at two stages;
insole issue and six months. The F-ScanW in-shoe pres-
sure measurement system is capable of reliable and re-
peatable data collection [16,17]. To optimise the
accuracy and repeatability of the data collected within
this study the following precautions were incorporated
within the data collection protocol. A new sensor was
provided for each individual foot, labelled and used to
collect data from that foot throughout the duration
of the study. Prior to calibration each sensor underwent
equilibration, was trimmed, and fitted into each
shoe. Before each data collection session each patient
was weighed and each pair of insoles calibrated against
body weight. Following calibration, if sensor saturation
pressure exceeded 2000 kPa the sensor was discarded.Calibration was then checked for within and between
foot repeatability, and if excessive variation was observed,
the sensor was re-calibration. Data were collected imme-
diately following sensor calibration, recording two test
conditions (with insoles and without insoles). Each test
condition consisted of three walking trials, first a learning
trial then two trials were recorded. The first and last step
of each walking was excluded to allow for gait acceleration
and deceleration. Gait velocity of each walking trial was
timed to check for consistency, in the event variation was
found the data was discarded and the test repeated. Parti-
cipants were asked to walk between two chairs placed at
either end of a walkway. Between the chairs, two marks
were placed on the floor with a distance of ten metres
between them. Using a stop watch, the time taken for the
participant to walk the ten metre distance was recorded
and then gait velocity was calculated in metres per second.
Participants underwent debridement of plantar callus
prior to data collection. Participants wore the standardised
therapeutic footwear provided and 20 denier stockings
during the collection of pressure data.
Data from one foot of each patient averaging a mini-
mum of six steps was used within the analysis; selected
as the foot recording the highest peak pressure value at
baseline. Five kinetic outcome measures between the
two groups, before and after the intervention, were used:
i. Peak pressure: highest value of peak pressure
calculated by dividing force by total contact area.
ii. Total contact area: total loaded plantar surface area
iii.Forefoot pressure time integral: forefoot peak
pressure multiplied by forefoot contact time,
displayed as the area under the pressure/time curve.
A forefoot mask was manually applied using the
F-scanW software, saved as an object file and then
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consistency of size and position.
iv.Rate of forefoot loading: peak forefoot force of
each foot strike divided by the time taken to reach
peak force.
v. Duration of load at the site of highest peak pressure.
Extracted using TAM analysis software (TEKSCANW
Ltd), the data is presented for the masked area as the
duration and variation of load as a percentage of
stance. The seven TAM analysis boxes were manually
positioned to overlie seven anatomical regions of one
movie display. The seven regions represented; the
hallux, first metatarsal, second metatarsal, third and
fourth metatarsal, fifth metatarsal, midfoot and heel.
To ensure consistency, the box positions were
saved to the system and then downloaded onto
subsequent trials.
Secondary outcome measures
Two self-report questionnaires validated for use with
individuals diagnosed with diabetes generated the scores
of perceived foot health (Bristol Foot Score) and health-
related quality of life (Audit of Diabetes Dependent
Quality of Life). The Bristol Foot Score is designed to
measure an individual’s perception of foot health, includ-
ing changes over time [18]. It contains 15 items grouped
into 3 components; (i) concerns about feet and pain, (ii)
footwear and general health, and (iii) mobility. The final
score ranges from 15 representing the best possible per-
ceived foot health to 73 corresponding with the worst.
The Audit of Diabetes Dependent Quality of Life
(ADDQoL) offers an individualised disease-specific
health-related quality of life measure [19]. The ADDQoL
allows participants to select domains of personal con-
cern and rate them according to current quality and im-
portance. The weighted domains are combined to
produce an individualised summary score of health-
related quality of life. The final score ranges from +9
representing a positive impact of diabetes on health-
related quality of life to −9 representing a negative impact
of diabetes on health-related quality of life.
Cost
Costs of insole provision, including direct and indirect
costs incurred in the supply and review of insoles and
footwear were compared. The prefabricated and custom-
made functional insoles cost £31.73 and £137.65
respectively. The provision of two pairs of therapeutic
footwear per participant cost £300. Staff time was calcu-
lated using marginal costs based on the 2008 gross pay for
a National Health Service (NHS) Band 7 clinician (UK) at
an hourly rate of £53.51 inclusive of salary and oncosts.
Participant travel and attendance costs were calculated
from information provided from participant completedquestionnaires at each clinic visit. Private transport costs
were calculated on NHS rates for private car use (£0.53
per mile), whilst participant and accompanying person
travel time was based upon the minimum wage for the
United Kingdom (October 2008, £5.73 per hour).Adherence and adverse events
Other recorded data included patient adherence
(monitored using a self-reported questionnaire completed
at each clinic visit) and a record of adverse events.Statistical analysis
The data analysis was carried out using intention to treat
including all participants randomised. Multiple imputa-
tions was used to address missing data, following the as-
sumption that the data were missing at random such
that the variables observed and recorded were predictive
of the missing data. IBM SPSS statistics version 19 was
used to impute the missing values and five imputed data
sets were created.
All variables met assumptions for parametric data,
therefore split plot ANOVAs using data collected at
issue and six month follow-up were used to compare the
custom-made functional and prefabricated insoles. Inde-
pendent sample t-tests were used to compare the cost of
providing the two different insoles. Statistical signifi-
cance for hypothesis tests was set at 0.05.Results
Participants and follow-up
A total of 127 people with diabetes and neuropathy re-
quiring treatment were invited to be assessed for eligibility
(Figure 2); five people declined and 122 were assessed.
Three did not meet the entry criteria, leaving 119 who
were recruited and randomised. Sixty participants were
allocated the custom-made functional insole and 59 the
prefabricated insole. Table 1 summarises the baseline
characteristics of participants. A total of 104 (87%)
participants completed the six month follow-up. The
characteristics of participants failing to complete were
similar between groups.Compliance in using the insoles
Of the 104 participants completing the six month fol-
low-up, 41 (40%) reported full compliance, i.e. reported
wearing insoles and shoes for a minimum of seven hours
per day, seven days a week for a period of six months,
whilst 79 (76%) reported 50% compliance equating
to wearing the insoles and shoes for a minimum of
five hours a day five days a week for the duration of
the study.
Patient requires treatment, referred for assessment of eligibility
(n=127)
Assessed for eligibility
(n=122)
Randomised (n=119)
Excluded (n=0)
Refused to participate (n=5)
Excluded (n=0)
Not meeting criteria (n=3)
Refused to participate (n=0)
Allocated to intervention (n=60)
Custom-made functional insole
Allocated to intervention (n=59)
Prefabricated insole
Demographic data collected 
Received intervention (n= 56)
1 died
1 moved from area
1 fell and hospitalised long term
1 withdrew from the study
Received intervention (n=57)
1 died
1 amputation of lower extremity
Completing 6-month follow up 
(n=51)
Lost to follow-up (n=6)
1 died
1 hospitalised terminal illness
1 housebound at follow up
2 withdrew from study
1 did not attend follow up
Competing 6-month follow up 
(n=53)
Lost to follow-up (n=3)
2 withdrew from study
1 did not attend follow up
6 month follow up primary end point (n=104)
kinetic data unavailable (n=8)
Figure 2 Participants journey through the trial.
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With the application of either type of insole there were
significant reductions in peak pressure, forefoot pressure
time integral and rate of forefoot loading, while total
contact area increased compared to no insole in the
shoe. For example, for the prefabricated insole, the peak
pressure was reduced from 566 to 363 kPa, the pressure
time integral from 57 to 45 kPa.sec, the reduction in
forefoot rate of load from 126 to 119 kPa/sec, and the
total contact area increased from 14219 to 18199 mm2.
Comparison of insoles
There was no difference between custom-made func-
tional and prefabricated insoles for peak pressure. Fore-
foot pressure time integral showed greater percent
reduction for the custom made functional insole at issue(27% vs. 22%, p=0.001) and at six months (30% vs. 24%,
p=0.001) (Table 2). The effect size was medium (Partial
Eta Squared 0.89). There was no difference for total con-
tact area, rate of forefoot loading, or duration of load. In
addition to the plantar pressure data, there were no dif-
ferences between custom-made functional insoles and
prefabricated insoles in participants’ Bristol Foot
Score or Audit of Diabetes Dependent Quality of Life
(Table 3). The custom-made functional insole was
more expensive (£656 vs. £554, p<0.001) to provide
than the prefabricated insole (Table 4).
Blind testing
To assess for bias and breaking the blinding process,
participants were asked at completion of the study to
guess their intervention group assignment. Of the 45
Table 1 Participant Characteristics
Demographic Data Custom-made
group
Prefabricated
group
(n=60) (n=59)
Mean age in years (SD) 71 (10) 70 (10)
Mean weight in kg (SD) 95 (16) 97 (21)
Mean height in metres (SD) 1.74 (0.27) 1.69 (0.13)
Mean BMI (SD) 32 (10) 32 (11)
Gender male/female 48/12 42/17
Diabetes Type I/II/unknown 2/57/1 2/57/0
Neuropathy 60 59
PVD 0 0
HbA1c % 8.1 (2.3) 7.7 (2.9)
Mean duration of diabetes in years (SD) 9 (9) 9 (8)
Plantar callus (yes/no) 25/35 22/37
Toe deformity (yes/no) 30/29
(1 missing)
29/30
Prior foot ulcer (yes/no) 5/55 6/53
Mean left foot peak pressure in kPa (SD) 499 (137) 498 (135)
Mean right foot peak pressure in
kPa (SD)
494 (142) 512 (174)
Mean forefoot PTI in kPa.sec (SD) 53 (17) 55 (16)
Mean rate of forefoot loading in
kPa/sec (SD)
118 (35) 126 (41)
Mean total contact area in mm2 (SD) 14778 (1996) 14171 (2083)
Foot type (Foot Posture Index ≥4) 25 19
Note: PTI = Pressure time integral.
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thought they had been given the custom-made func-
tional insole, 4 (8%) thought they had the prefabricated
insole and 16 (36%) did not know. Of the 46 respon-
dents receiving the custom-made functional insole, 30
(65%) thought they had been given the custom-made in-
sole, 4 (9%) thought they had been given the pre-
fabricated insole and 12 (26%) did not know. A total of
34 (37%) participants chose the intervention received, 29
(32%) guessed incorrectly and 28 (31%) were unable to
decide which insole they had been provided. Participants
remained blind to the intervention allocation for the trial
duration.
Adverse events
Five (4%) of the 119 recruited participants developed ad-
verse effects whilst participating in the trial. Four of the
five had been randomly allocated the prefabricated in-
sole: one developed a Charcot joint and the other three
plantar ulcers, one of which was apparently caused by a
sock being inadvertently left in the toe of a shoe while
worn. One further participant that experienced an ad-
verse event had received the custom-made insole: at fol-
low-up, a 1st interphalangeal joint ulcer was discoveredin conjunction with suspected osteomyelitis, so the par-
ticipant was immediately withdrawn from the study to
be managed appropriately.
Discussion
Both insoles were comparable in reducing peak pressure
(for all foot types) and rate of forefoot loading whilst
increasing total contact area, but the custom-made func-
tional insoles were more expensive than the prefabri-
cated insoles. Peak pressure is the measure that has been
traditionally used in studies evaluating the effect of off-
loading. However, in addition, we used four other mea-
sures. For one of these, forefoot pressure time integral,
the custom-made insoles performed significantly better,
and these differences were maintained over the six
month study period.
Total peak pressure was selected as the traditional
measure of the effect of footwear and insole efficacy to
ease comparison of results between studies. Forefoot
pressure time integral was selected to reflect the
increased risk of ulceration over the forefoot. More re-
cently it has been reported that peak pressure and pres-
sure time integral are inter-dependent and that within
clinical trials significant differences in patterns found be-
tween the two parameters are generally minimal [20,21].
Thus, there is little value in routinely reporting both
measures [20,21]. We acknowledge, therefore, that fore-
foot peak pressure would have been an equally suitable
measure and accept that our findings are likely to have
been the same if forefoot peak pressure had been
selected [20,21].
No other randomised controlled trial has been identi-
fied to indicate that custom-made functional insoles are
significantly more effective in reducing forefoot pressure
time integral or forefoot peak pressure than prefabri-
cated insoles when used to reduce ulcer risk in neuro-
pathic diabetic feet. Reductions in peak pressure
observed at insole issue in our study (31-37%) are, how-
ever, comparable to peak pressure reductions demon-
strated by other non-randomised studies (32%) [22,23].
At six month follow-up, peak pressure reductions
observed in our trial (Prefabricated 31%, Custom-made
functional 37%) appear better than findings presented
elsewhere. Mohamed and colleagues [22] compared a
custom plastazote orthosis to a custom aliplast/plasta-
zote orthosis in two groups of eight people with diabetic
neuropathy and reported peak pressure reduction of
26% at three months. Lobman and colleagues [23] com-
pared 18 participants with neuropathy provided with
custom made EVA insoles in therapeutic shoes with 63
controls and reported a mean reduction in peak pressure
of 28% at six months. The apparent enhanced perform-
ance across time of the insoles evaluated by our trial
may reflect the greater durability of materials selected.
Table 2 Outcomes and between group comparisons across time for peak pressure, forefoot pressure time integral,
total contact area and forefoot rate of loading
Outcome Custom-made functional Prefabricated Overall
significance*
Baseline 6-months Baseline 6-months (all randomised)
Actual % 95% CI Actual % 95% CI Actual % 95% CI Actual % 95% CI
Peak pressure reduction kPa 189 37 40, 33 239 37 42, 33 199 35 39, 31 187 31 34, 26 F=2.687
(111) (15) (171) (14) (115) (15) (141) (17) Eta2=0.023
p=0.104
Forefoot pressure time integral
reduction kPa.sec
14 27 29, 24 18 30 32, 27 12 22 25, 20 15 24 26, 21 F=11.276
(10) (11) (12) (10) (7) (8) (12) (10) Eta2=0.089
p=0.001
Total contact area increase mm2 4285 32 30, 35 2443 15 13, 16 3827 29 27, 32 2395 15 14, 16 F=1.66
(1464) (10) (1147) (5) (1183) (9) (803) (5) Eta2=0.014
p=0.20
Forefoot rate of loading reduction
KPa/sec
4 3 6, 0.4 7 4 8, 0.6 7 6 9, 3 6 3 6, 0.7 F=0.225
(11) (13) (16) (14) (13) (11) (17) (13) Eta2=0.002
p=0.636
Values are mean and (SD).
% is the actual difference expressed as a percentage of ‘no-insole’.
*ANOVA; significance of difference in % change between custom-made functional and prefabricated insoles over 6 months.
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fications to the plastazote insoles after only one month of
use to compensate for material compression.
Reduction in peak plantar pressure is believed to result
from a corresponding increase in total surface area.
We found that although both insoles increased total
contact area significantly, that change had reduced by
50% at six months follow-up. If peak pressure was
strongly associated with total contact area, a reduc-
tion in total contact area would generate an asso-
ciated increase in peak pressure. Conversely, the
results of our study found that at six months follow-
up, whilst the effect of the insoles on total contact
area had decreased, the effect on peak pressure stayed
constant.Table 3 Outcomes and between group comparisons across tim
Dependent Quality of Life
Outcome Custom-made functional (n=60)
Baseline 95% CI 6 month 95% C
Bristol Foot Score 44 41, 47 41 39, 44
(13) (12)
Audit of Diabetes Dependent
Quality of Life
−2.2 −2.7, -1.7 −2.54 −3.1, -1
(1.8) (2.27)
Values are mean and (SD).
*ANOVA; significance of difference in patient-based measures between custom-madThe absence of association between peak pressure and
total contact area in this trial may be explained by con-
sidering the dynamic nature of the data. Most peak pres-
sure sites were located over the forefoot during
propulsion. In contrast, the insole generated the greatest
increase in surface area beneath the medial longitudinal
arch, at midstance. Thus, the effect of increased total
contact area on peak pressure at midstance may not
carry over into propulsion. The mechanism by which
insoles reduce plantar peak pressure is unclear and in
need of further investigation.
Two non-randomised studies confirm an increase in
total contact area when insoles were worn [24,25].
Albert and Rinoie [26] recorded a 5-10% increase in
total contact area when a rigid custom-made device wase for Bristol Foot Score and Audit of Diabetes
Prefabricated (n=59) Overall significance*
I Baseline 95% CI 6 month 95% CI (all randomised)
42 39, 45 40 37, 43 F=0.449
(12) (11) Eta2=0.004
p=0.481
.9 −2.39 −2.8, -1.9 −2.39 −3.0, -1.8 F=0.002
(2.06) (2.5) Eta2=0.000
p=0.963
e functional and prefabricated insoles over 6 months.
Table 4 Comparison of costs between the two insoles
Outcome Mean
Cost (£)
Custom-made
functional
Prefabricated Overall
significance*
Insole 137.65 31.73 (Fixed price)
Clinician time 158.28 (49.55) 163.59 (40.75) t=0.638, p=0.525
Patient time 16.95 (5.31) 17.53 (4.36) t=0.649, p=0.517
Patient travel 43.15 (22.39) 41.44 (16.72) t=−0.470, p=0.639
Total 656.03 (69.56) 554.28 (53.34) t=−8.942, p<0.001
Values are mean cost (£) and (SD).
*Independent sample t-tests; significance of difference between custom-made
functional and prefabricated insole groups.
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period. Raspovic and colleagues [24] used the F-scanW to
evaluate change in contact area, testing a range of custo-
mised accommodative insoles in a sample of 8 high risk
people with diabetic neuropathy and a history of ulcer-
ation. A 19% increase in total contact area was found
when wearing the insole, no follow-up evaluation was
undertaken. In comparison, our study reported a sub-
stantially greater total contact area increase of 32% and
29% for the custom-made functional and prefabricated
insoles at issue, reducing to 15% at six months.
Differences between study results may be attributed to
differences in methodology. Raspovic and colleagues
[24] investigated the effect of previously worn non-
casted custom-made insoles on total contact area. Com-
pared to our study insoles, the profile of the non-casted
device may be less contoured, thus reducing the com-
parative total surface area. Equally the 19% increase in
total contact area reported by Raspovic and colleagues
[24] may reflect the time from issue; their findings are
comparable with the 15% increase reported by our study
at six month follow up.
Albert and Rinoie [25] included only people with dia-
betes and pronated feet. The contact area beneath
pronated feet is high, thus reducing the capacity for an
insole to further increase total contact area. A greater
effect therefore might be predicted in a sample popula-
tion not limited by foot type, such as that recruited for
our trial (44 out of 119 had pronated feet in our sample).
Furthermore, unlike our semi-rigid insoles, the insole
investigated by Albert and Rinoie [25] was of rigid con-
struction, unlikely to flex under load. Differences in
insole flexibility offer further explanation for differences
in change in total contact area reported between studies.
The custom-made functional device fabricated for
clinical use is commonly prescribed to include the bio-
mechanical features best suited to foot type (pronated or
supinated). Likewise, the custom-made functional device
designed for this trial incorporated biomechanical fea-
tures specific to foot type in conjunction with features
considered safe for the insensate foot. More than one
third of study participants randomised to the custom-made functional insole group (n=25/60) received an in-
sole intended to benefit the pronated foot. Although dir-
ect comparison between studies is not possible, the 37%
reduction in peak pressure achieved by the custom-
made insole in this trial appears similar to the clinical
benefit achieved by the rigid device evaluated by
Albert and Rinoie.
The outcome measure, duration of load as a percent-
age of stance at the site of peak pressure was included in
recognition of the contribution toward ulceration that
increased load times are thought to play [26,27]. No
other study considering this measurement was found in
the literature. The effect of wearing insoles on duration
of load as a percentage of stance was variable and incon-
sistent between participants and when the same partici-
pant was measured on different occasions. Duration of
load as a percentage of stance over the site of peak pres-
sure cannot easily be altered by insole therapy and does
not appear a suitable measurement to assess the effect
of insoles in people with diabetes and neuropathy. How-
ever, given the limited research using this outcome
measure, further work is required to determine whether
these findings are representative of a general trend
before a final conclusion can be drawn.
This study found that wearing insoles reduced rate of
forefoot loading in the diabetic neuropathic foot, al-
though the effect was small. It has been suggested that
rate of forefoot loading maybe as important as the mag-
nitude of load in ulcer formation [28], although an asso-
ciation with ulceration has not been determined. The
only other study that we have found that assessed
change in rate of loading in the evaluation of insoles for
the management of the neuropathic foot [24], was non-
randomised and recruited only eight participants so was
likely to be under-powered.
Neither the ADDQoL nor the Bristol Foot Score
showed any difference between the two insoles. Com-
pared to other populations with diabetes, this sample of
119 participants with diabetic peripheral neuropathy had
worse health-related quality of life. A survey of 795 out-
patients attending annual review at a UK hospital
diabetes clinic reported mean weighted impact score for
health-related quality of life of −1.98, which compares to
a mean weighted score for participants in this trial of
−2.38 [29]. No other study has employed the ADDQoL
to capture the impact of diabetic peripheral neuropathy
on health-related quality of life.
The estimated direct cost of treating a diabetic ulcer
over a 12 year period is £27,000 [30]. Assuming insoles
are replaced annually and footwear two yearly, the esti-
mated cost of insole provision over a 12 year period was
calculated at £4771 and £3500 for the custom-made
functional and prefabricated insole respectively. There-
fore, each diabetic foot ulcer prevented by insole
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£23,000. Full utility analysis using longitudinal measures
of time to foot ulceration or life expectancy is needed to
provide robust economic analysis of insoles for diabetic
neuropathic foot ulceration.
There is no clear evidence that the custom-made func-
tional or prefabricated insole is best practice for all dia-
betic neuropathic feet, however both are of value for
reducing ulcer risk in people with diabetes and neur-
opathy. Both custom-made functional and prefabricated
insoles were equally effective in reducing peak pressure;
therefore the less expensive prefabricated insole is likely
to be most cost effective. Practitioners tasked with acces-
sing the diabetic foot for insole provision should, where
appropriate, consider prescribing the more cost effective
prefabricated insole. The custom-made functional insole
was found slightly more effective than its cheaper counter-
part in reducing forefoot pressure time integral. The clin-
ical significance of reducing forefoot pressure remains
undetermined. Further research is needed to determine;
(i) which parameter is more important in predicting
neuropathic foot ulceration, (ii) the magnitude of reduc-
tion deemed clinically sufficient to produce a symptom
change, and (iii) confirmation of costs over time.
Of the 104 participants completing our study, 42
(40%) reported full compliance equating to wearing the
insoles and shoes for a minimum of 7 hours a day, 7
days per week for a period of six months [31]. Chantelau
and Haage [31] reported that participants with diabetic
neuropathy and a history of foot ulceration, wearing pro-
tective shoes for >60% of the daytime reduced ulcer re-
lapse rate by 50%. Thus, for the purposes of this study,
60% of daytime wear of insoles and footwear for the dur-
ation of the six month study were considered compliant.
Footwear compliance within this trial, although appar-
ently low, is favourable compared to compliance rates
reported elsewhere [31,32]. Three participants did not
wear the insoles because they felt unstable when walking
with them. However, the most common reason given by
participants for not wearing the insoles and shoes for
more hours per day, was that they were being removed
whilst indoors, despite footwear education to the con-
trary. Improving insole and footwear compliance in
patients presenting with diabetic neuropathy is crucial to
the success of diabetic foot health maintenance. Insole
compliance may be improved if patients were provided
with both indoor and outdoor footwear to accommodate
insoles.
This study needs to be considered in light of a few
limitations. Firstly, although all the tests were pre-speci-
fied, by exploring four outcomes, in addition to peak
pressure, we increased the possibility of finding a sig-
nificant result by chance. However, even adjusting the
p-value for multiple testing, the difference in pressuretime-integral is significant. Secondly, the clinical en-
vironment we used to collect data may not fully repli-
cate the day-to-day conditions within which the
insoles are required to function. The choice of foot-
wear used to accommodate insoles can affect func-
tion. Therefore, care must be taken not to generalise
the findings of this trial beyond the type of thera-
peutic footwear provided within the study. The six
month follow up in our trial gave limited information
regarding insole durability. In practice, frequency of
insole replacement often extends beyond six months
and is usually determined by physical signs of insole
wear or changes in foot health. Finally, application to
clinical practice may be enhanced if future studies
were specific not only to foot pathology but foot type
(pronated or supinated). The implication that forefoot
pressure time integral and other selected variables are
symbolic of ulceration risk is too simplistic and
should be approached with caution; the aetiology of
diabetic neuropathic ulceration is multi-factorial and com-
plex, therefore whilst clearly relevant to ulceration risk,
kinetic parameters are merely surrogate measures of in-
ternal tissue stress. Moreover, the actual pressure thresh-
old generating internal tissue stress above which
ulceration is inevitable is undetermined, therefore
estimates of clinical significance are difficult to pre-
dict. Further studies are required using a randomised
controlled trial design to assess insoles used for the
prevention of diabetic neuropathic foot ulceration,
particular attention should be given to the compari-
son of insole type using incidence of ulceration as a
primary measure of outcome.
Conclusion
This randomised controlled trial is novel in its comparison
of insoles designed specifically to address the neuropathic
foot-related biomechanical complications associated with
ulceration development. Moreover, it is one of very few
randomised controlled trials to control for footwear. The
relevance to clinical practice is enhanced by the recruit-
ment of a sample population including patients presenting
with diabetic peripheral neuropathy but excluding periph-
eral arterial disease. The findings provide further evidence
to suggest that insoles are of value and should form part
of the plantar load reducing strategy for the diabetic
neuropathic foot. Custom-made insoles are more expen-
sive than prefabricated insoles and from our findings, no
better in reducing risk. We recommend that practitioners
tasked with accessing the diabetic foot for insole provision
should, where appropriate, consider prescribing the more
cost effective prefabricated insole. Insole and footwear
compliance remains an issue and must be improved to
enable the diabetic neuropathic population to fully benefit
from any treatment effect.
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